BioXgen, a medical device company developing a cardiac patch to prevent post-operative atrial fibrillation (POAF), has opened a Community Investment Round under Regulation Crowdfunding. POAF is the most common complication following open-heart surgery, affecting approximately 50% of the 500,000 Americans who undergo the procedure annually. This condition significantly increases risks of stroke, recurrent atrial fibrillation, kidney failure, and death, with the U.S. healthcare system bearing approximately $9 billion in related costs each year.
The company's cardiac patch is placed directly on the heart's surface during surgery. Pre-clinical data published in Circulation demonstrated a reduction in POAF rates from about 50% to under 5%, representing a tenfold improvement. Unpublished data from over 200 additional patients have shown similar results. BioXgen has completed its Q-submission to the FDA and is pursuing clearance through the 510(k) pathway, which establishes substantial equivalency to previously cleared materials. The company targets total development time to clearance at under 18 months, pending critical funding needs.
The investment offering is structured as Regulation Crowdfunding and hosted by DealMaker Securities, with investments starting at $500. This approach allows retail investors to participate in a medical device category traditionally reserved for institutional capital. BioXgen maintains a lean operational structure with contracted manufacturing, a growing intellectual property portfolio, and a capitalization table designed to accommodate both community investors and institutional partners.
Dr. David Skinner, BioXgen's President and CEO, stated, "We have the data, the regulatory path, the clinical partner, and the team that has done this before. This round lets people outside the institutional world participate in a device that solves a real problem." The company aims to establish the device as standard of care within 36 to 48 months following FDA clearance. Dr. Skinner and Chief Science Officer Dr. John P. Konhilas will present the full 2026 Community Investment Round pitch deck during a live webinar on April 7, 2025, accessible through registration.
Prospective investors can review the offering details and investment information at https://invest.bioxgen.life/. BioXgen has filed a Form C with the Securities and Exchange Commission in connection with its offering, with documentation available through the same platform. The company's approach represents a potential shift in addressing a significant healthcare challenge that has persisted without approved solutions despite decades of off-label pharmaceutical use by surgeons.
